2003
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma
Oh W, Halabi S, Kelly W, Werner C, Godley P, Vogelzang N, Small E, B F. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma. Cancer 2003, 98: 2592-2598. PMID: 14669278, DOI: 10.1002/cncr.11829.Peer-Reviewed Original ResearchConceptsGranulocyte-colony-stimulating factorHormone-refractory prostate carcinomaPretreatment prostate-specific antigenGranulocyte-colony-stimulating factor supportProstate carcinomaMedian time to disease progressionTime to disease progressionAdvanced prostatic carcinomaCombination of estramustineAndrogen deprivation therapyGrade 4 toxicityCycles of therapyPhase II studyProstate-specific antigenOverall survival periodCooperative group studiesComplete responseDeprivation therapyFebrile neutropeniaPartial responseFactor supportToxicity profileGrade 3DocetaxelCarboplatin
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS FoodDocetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh W, Kantoff P. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Seminars In Oncology 1999, 26: 49-54. PMID: 10604270.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerCombination of estramustineHormone-refractory diseaseProstate cancerWeekly docetaxelTreatment of hormone-refractory prostate cancerHigh-risk localized prostate cancerTreatment of hormone-refractory diseaseHigh-risk localized diseaseLocally advanced prostate cancerTaxane-based chemotherapy regimensGranulocyte colony-stimulating factorSingle-agent activityLocalized prostate cancerAdvanced prostate cancerTaxane-based regimensColony-stimulating factorHormone-refractorySystemic relapseEscalating dosesChemotherapy regimensMetastatic diseaseLocalized diseaseClinical courseChemotherapy agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply